Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis

Journal of Neurology

Volumn 262, Issue 8, 2015, Pages 1859-1866

  Zekeridou, Anastasia ^a   Karantoni, Evgenia ^a,d   Viaccoz, Aurélien ^a,b,c   Ducray, François ^a,b,c   Gitiaux, Cyril ^e   Villega, Frédéric ^f   Deiva, Kumaran ^g   Rogemond, Veronique ^a,b   Mathias, Elodie ^a,b   Picard, Géraldine ^a   Tardieu, Marc ^g   Antoine, Jean Christophe ^a,h   Delattre, Jean Yves ^d   Honnorat, Jerome ^a,b,c  

^a HÔPITAL NEUROLOGIQUE   (France)

^b LYON NEUROSCIENCE RESEARCH CENTER   (France)

^c UNIVERSITÉ LYON 1   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT COCHIN   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h HOSPICES CIVILS DE LYON   (France)

Author keywords

NMDA receptor encephalitis; Pediatric autoimmune encephalitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RITUXIMAB;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; ENCEPHALITIS; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; RANKIN SCALE; RELAPSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; INFANT; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; AGE FACTORS; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOTHERAPY; INFANT; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PLASMA EXCHANGE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84939268946     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7781-9     Document Type: Article

References (24)

1. Dalmau J, Tu E, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic anti—N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36. doi:10.1002/ana.21050
2. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J (2009) Anti—N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 66:11–18. doi:10.1002/ana.21756
3. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese Ma, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A (2010) N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667. doi:10.1093/brain/awq113
4. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10:63–74. doi:10.1016/S1474-4422(10)70253-2
5. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165. doi:10.1016/S1474-4422(12)70310-1
6. Armangue T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, Dalmau J (2013) Pediatric anti-N-methyl-d-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 162:850–856. doi:10.1016/j.jpeds.2012.10.011
7. Wright S, Hacohen Y, Jacobson L, Agrawal S, Gupta R, Philip S, Smith M, Lim M, Wassmer E, Vincent A (2015) N-methyl-d-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child. doi:10.1136/archdischild-2014-306795
8. Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, Meissirel C, Honnorat J, Groc L (2012) Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 135:1606–1621. doi:10.1093/brain/aws092
9. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Dessain SK, Rosenfeld MR, Balice-gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098. doi:10.1016/S1474-4422(08)70224-2.Anti-NMDA-receptor
10. Hacohen Y, Absoud M, Hemingway C, Jacobson L, Lin J-P, Pike M, Pullaperuma S, Siddiqui A, Wassmer E, Waters P, Irani SR, Buckley C, Vincent A, Lim M (2014) NMDA receptor antibodies associated with distinct white matter syndromes. Neurol Neuroimmunol Neuroinflamm 1:e2. doi:10.1212/NXI.0000000000000002
11. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan Pa, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M (2014) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 83:142–150. doi:10.1212/WNL.0000000000000570
12. Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J (2010) In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 5:31. doi:10.1186/1750-1172-5-31
13. Lancaster E, Dalmau J (2012) Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 8:380–390. doi:10.1038/nrneurol.2012.99
14. Camdessanché J-P, Streichenberger N, Cavillon G, Rogemond V, Jousserand G, Honnorat J, Convers P, Antoine J-C (2011) Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. Eur J Neurol 18:929–931. doi:10.1111/j.1468-1331.2010.03180.x
15. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J (2011) Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 77:589–593
16. Kosmidis ML, Dalakas MC (2010) Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 3:93–105. doi:10.1177/1756285609356135
17. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS (2009) Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 66:1016–1021
18. Binstadt B, Caldas A, Turvey S, Weinstein H, Jackson J, Fuhlbrigge R, Sundel R (2003) Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 143:598–604
19. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4:259–266. doi:10.1177/1756285611411503
20. Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110–1117. doi:10.1001/jamaneurol.2013.3071
21. Fekete R, Jankovic J (2012) Childhood stiff-person syndrome improved with rituximab. Case Rep Neurol 4:92–96. doi:10.1159/000339446
22. Battaglia T, De Grandis E, Mirabelli-Badenier M, Boeri L, Morcaldi G, Barabino P, Intra C, Naselli F, Pistoia V, Veneselli E, Conte M (2012) Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. Eur J Paediatr Neurol 16:192–195. doi:10.1016/j.ejpn.2011.05.013
23. Tatencloux S, Chretien P, Rogemond V, Honnorat J, Tardieu M, Deiva K (2015) Intrathecal treatment of anti-N-methyl-d-aspartate receptor encephalitis in children. Dev Med Child Neurol. 57(1):95–99. doi:10.1111/dmcn.12545
24. DeSena AD, Greenberg BM, Graves D (2014) Three phenotypes of anti-N-methyl-d-aspartate receptor antibody encephalitis in children: prevalence of symptoms and prognosis. Pediatr Neurol 51:542–549. doi:10.1016/j.pediatrneurol.2014.04.030